AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06662916 — intervention group
Intervention type: BEHAVIORAL
Intervention: Microbiota-Diversity Enhancing Diet on children with Autism Spectrum Disorder
Description: Microbiota-Diversity Enhancing Diet on Children with ASD (MIND-DASE) suggested that increasing microbiota diversity through dietary interventions can have significant benefits on the neurodevelopmental outcomes of children with ASD
Study NCT01805258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
Study NCT03294434 — intervention group
Intervention type: OTHER
Intervention: Diffusion tensor Imaging (DTI)
Description: Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
Study NCT02259621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 Therapy
Study NCT02624817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: See Arm description.
Study NCT03146507 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasound
Description: ultrasound assessment of gestational age, amniotic fluid index, and fetal weight
Study NCT02259621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Anti-PD-1 Therapy
Study NCT02259621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Anti-PD-1 Therapy
Study NCT02259621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Anti-PD-1 Therapy
Study NCT03146507 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Doppler ultrasound
Description: Umbilical artery and Middle cerebral artery Doppler blood flow assesment
Study NCT05107986 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic repair
Description: All patients of cohort underwent laparoscopic repair.
Study NCT01083433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes related psychological counseling and education
Description: The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
Study NCT01083433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor
Description: Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
Study NCT04250324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BZ019
Description: A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
Study NCT03981406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
Study NCT03146507 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Fetal echocardiography
Description: The cardiac output (ratio between right side cardiac outputs to left side cardiac output) was calculated
Study NCT03981406 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Control group will receive standard of care treatment for IPF.
Study NCT03554122 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shotblocker
Description: Patients spinal injections were performed with Shotblocker placed onto injection site
Study NCT01906034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise with supervision
Study NCT01906034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based without supervision
Study NCT03338673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function
Study NCT03338673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BrainHQ
Description: BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
Study NCT00538707 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-minute Bondet test
Description: 2-minute Bondet test
Study NCT02006355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02006355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT01932801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XR-NTX
Study NCT01932801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01932801 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HRC
Study NCT01932801 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HRC
Study NCT01932801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRC
Study NCT04181294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual practice
Description: Baseline practice of ICU communication and care planning
Study NCT03450317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 80mg
Description: No treatment
Study NCT01139775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously as a continuous 10-minute infusion
Study NCT01139775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered intravenously as a continuous 10-minute infusion
Study NCT01139775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered intravenously as a continuous 1-hour infusion
Study NCT01139775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously as a continuous 1-hour infusion
Study NCT01139775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Description: Administered intravenously as a continuous 1-hour infusion
Study NCT00039559 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Early detection
Description: CA125 is measured in blood and the longitudinal results interpreted with a statistical algorithm to determine if there has been a significant increase from baseline.
Study NCT04655560 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: qualitative study
Study NCT04561934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver diamine fluoride
Description: Application of 38% SDF (Riva Star, SDI, Bayswater, Australia), and Resin modified glass ionomer cement (RMGIC) (Fuji Lining LC; GC, Tokyo, Japan) prior resin composite restoration (Filtek Z350 XT,3MESPE).
Study NCT04561934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin modified glassionomer cement
Description: resin modified glassionomer cement
Study NCT04057573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study NCT04057573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study NCT04057573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study NCT00803530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATO + Ascorbic acid
Description: ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution.
Study NCT02955394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
Study NCT02955394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
Study NCT02955394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: 500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
Study NCT01281631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001
Description: Low dose of NP001
Study NCT01281631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001
Description: High dose of NP001
Study NCT01281631 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study NCT01450150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: 20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
Study NCT01450150 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
Study NCT01819701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LC-1000
Description: L-carnitine 1000 mg /d
Study NCT01819701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LC-2000
Description: L-carnitine: 2000 mg/d
Study NCT01819701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Q10-150
Description: Coenzyme Q10: 150 mg/d
Study NCT01819701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Q10-300
Description: Coenzyme Q10: 300 mg/d
Study NCT01819701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01270607 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Treatment given twice per week for 4 weeks
Study NCT03403712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosnetupitant/ palonosetron
Description: intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
Study NCT03403712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: netupitant/palonosetron
Description: oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
Study NCT03403712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Oral dexamethasone (12 mg)
Study NCT03403712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral dexamethasone (12 mg)
Study NCT04567160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: In the propofol group, general anesthesia will be induced using target-controlled infusion (TCI) of propofol and remifentanil. Marsh pharmacokinetic model will be used to set the initial target predicted effect-site concentration of propofol at 3.0 mcg/ml in flash mode. Simultaneously, target-controlled infusion of remifentanil will be started to reach an initial target predicted effect-site concentration of 3 ng/mL using the Minto pharmacokinetic model.~After tracheal intubation, TCI of remifentanil is paused.
Study NCT04567160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: In the sevoflurane group, induction of general anesthesia will be carried out by spontaneous breathing through a mask while progressively opening up the dial of the sevoflurane vaporizer up to 8%. Like in the propofol group, target-controlled infusion of remifentanil is simultaneously started to reach an initial target predicted effect-site concentration of 3 ng/mL. Vaporizer is adjusted when gas equilibration reaches the patient-specific concentration 1.0 MAC of sevoflurane. After tracheal intubation, TCI of remifentanil is paused.
Study NCT01990079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
Study NCT01990079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
Study NCT01990079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine replacement therapy
Description: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
Study NCT01990079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy
Description: Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
Study NCT01990079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
Study NCT01990079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling
Description: Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
Study NCT01990079 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mobile contingency management
Description: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
Study NCT01990079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile contingency management
Description: Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
Study NCT01990079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stay Quit Coach
Description: Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
Study NCT02314949 — intervention group
Intervention type: PROCEDURE
Intervention: intestinal transplantation
Study NCT00719758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRK-100STP (BERASUS LA)
Description: oral
Study NCT00719758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120 (Kremezin®)
Description: oral
Study NCT05152004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pariet
Description: Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
Study NCT05152004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pariet
Description: Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
Study NCT05152004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amolin
Description: Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
Study NCT05152004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amolin
Description: Rabeprazole 20 mg and amoxicillin 750 mg qid for 14 days
Study NCT05152004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid
Description: Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
Study NCT05152004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl
Description: Rabeprazole 20 mg and amoxicillin 1 g bid. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg bid. for 7 days
Study NCT00731601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole
Description: pantoprazole 40 mg/q6h IV infusion for three days
Study NCT00731601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: pantoprazole 8 mg/h IV infusion for three days
Study NCT04149769 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Indego Exoskeleton
Description: Regular dosing of Indego Exoskeleton walking.
Study NCT02298595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 IV day 1 of each cycle
Study NCT02298595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: XXXX day 1, 8, and 15 of each cycle
Study NCT02298595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: 200, 250, 300, or 350 mg/day by mouth every day
Study NCT03771768 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Diode laser 980nm&100 mWatt
Description: Diode laser 980 nm \&100 milli Watt.
Study NCT03771768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: 0.1 \&5gm paste 4 times/day
Study NCT02490527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pure epicatechin capsules (50mg)
Description: Epicatechin is a compound found naturally in dark chocolate.
Study NCT02490527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin (40mg)
Description: A cholesterol-lowering medication that blocks the production of cholesterol.
Study NCT02490527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin (40mg)
Description: A cholesterol-lowering medication that blocks the production of cholesterol.
Study NCT02490527 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance that has no therapeutic effect and will act as a control.
Study NCT02093468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MST-188
Study NCT02093468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00713622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
Study NCT00713622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium valproate
Description: Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
Study NCT02379650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Study NCT02379650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo